✦ LIBER ✦

Impact of Valganciclovir Prophylaxis on the Development of Severe Late-Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients

✍ Scribed by C. Cervera; M. Pineda; L. Linares; M.A. Marcos; C. Esteva; A. Antón; F. Cofán; M.J. Ricart; M. Navasa; F. Pérez-Villa; T. Pumarola; A. Moreno

Book ID: 116933649
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 62 KB
Volume: 39
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2007.07.039

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk of cytomegalovirus disease in high-

Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis

✍ Kalil, Andre C.; Mindru, Cezarina; Botha, Jean F.; Grant, Wendy J.; Mercer, Davi 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB

Valganciclovir prophylaxis in patients a

Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease

✍ D.J. Taber; E. Ashcraft; G.M. Baillie; S. Berkman; J. Rogers; P.K. Baliga; P.R. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

The Efficacy and Safety of 200 Days Valg

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

✍ A. Humar; Y. Lebranchu; F. Vincenti; E. A. Blumberg; J. D. Punch; A. P. Limaye; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

Oral Valganciclovir Is Noninferior to In

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

✍ A. Åsberg; A. Humar; H. Rollag; A. G. Jardine; H. Mouas; M. D. Pescovitz; D. Sga 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

Long-Term Outcomes of CMV Disease Treatm

Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients

✍ A. Åsberg; A. Humar; A. G. Jardine; H. Rollag; M. D. Pescovitz; H. Mouas; A. Big 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

Regarding: Humar et al. The Efficacy and

Regarding: Humar et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients. Am J Transplant 2010;10:1228–1237

✍ C. da Cunha-Bang; M. Iversen; S. A. Mortensen; A. Rasmussen; H. Sengeløv; S. S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB